Breast cancer screening in young women


      Breast cancer is the leading cause of death by cancer in women aged less than 40. However, organized screening of young healthy women has been recognized as inefficient and even deleterious by most experts [1], and should not been offered. Individualized screening, targeting only some young high-risk women, may be beneficial although no randomized trial has proven an impact on breast cancer mortality. All recommendations are based on expert’s opinions. This review offers a toned overview of these recommendations and underlines the need of careful information and shared decision with each patient.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


        • Siu A.L.
        • on behalf of the U.S. Preventive Services Task Force
        Screening for breast cancer: U.S. preventive services task force recommendation statement.
        Ann Intern Med. 2016; 164: 279-296

        • Pollan M.
        Epidemiology of breast cancer in young women.
        Breast Cancer Res Treat. 2010; 123: 3-6
        • Fredholm H.
        • Eaker S.
        • Frisell J.
        • Holmberg L.
        • Fredriksson I.
        • Lindman H.
        Breast cancer in young women: poor survival despite intensive treatment.
        PLoS One. 2009; 4: e7695
        • Jørgensen K.J.
        • Zahl P.H.
        • Gøtzsche P.C.
        Breast cancer mortality in organised mammography screening in Denmark: comparative study.
        BMJ. 2010; 340: c1241
        • Desreux J.
        • Bleret V.
        • Lifrange E.
        Should we individualize breast cancer screening?.
        Maturitas. 2012; 73: 202-205
        • Mavaddat N.
        • Antoniou A.C.
        • Easton D.F.
        • Garcia-Closas M.
        Genetic susceptibility to breast cancer.
        Mol Oncol. 2010; 4: 174-191
        • Tischkowitz M.
        • Tavtigian S.V.
        • Nathanson K.L.
        • et al.
        Gene-panel sequencing and the prediction of breast cancer risk.
        N Engl J Med. 2015; 372: 2243-2257
        • Canisius S.
        • Dennis J.
        • Lush M.J.
        • et al.
        Large-scale genotyping identifies 41 new loci associated with breast cancer risk.
        Nat Genet. 2013; 45: 353-361
        • Giannakeas V.
        • Narod S.A.
        The expected benefit of preventive mastectomy on breast cancer incidence and mortality in BRCA mutation carriers, by age at mastectomy.
        Breast Cancer Res Treat. 2017;

        • McMahon P.M.
        • Gilmore M.E.
        • Cott Chubiz J.E.
        • et al.
        Annual screening strategies in BRCA1 and BRCA2 gene mutation carriers: a comparative effectiveness analysis.
        Cancer. 2012; 118: 2021-2030
        • Halpern E.F.
        • Ryan P.D.
        • Weinstein M.C.
        • et al.
        Breast cancer screening in BRCA1 mutation carriers: effectiveness of MR imaging – Markov Monte Carlo decision analysis.
        Radiology. 2008; 246: 743-771
        • Nelson H.D.
        • Fu R.
        • Goddard K.
        • Mitchell J.P.
        • Okinaka-Hu L.
        • Pappas M.
        • et al.
        Risk assessment, genetic counseling, and genetic testing for BRCA-related cancer: systematic review to update the U.S. preventive services task force recommendation.
        Agency Healthc Res Qual (US). 2013;
        • Berrington de Gonzalez A.
        • Berg C.D.
        • Visvanathan K.
        • Robson M.
        Estimated risk of radiation-induced breast cancer from mammographic screening for young BRCA mutation carriers.
        J Natl Cancer Inst. 2009; 101: 205-209
        • Bartels K.
        • Menke-Pluymers M.
        • Eggermont A.
        • et al.
        A BRCA1/2 carriers, high breast density and prominent pushing margins of a tumor independently contribute to a frequent false-negative mammography.
        Int J Cancer. 2002; 102: 91-95
        • Tilanus-Linthorst M.M.
        • Obdeijn I.G.
        • Hop W.C.
        BRCA1 mutation and young age predict fast breast cancer growth in the Dutch, United Kingdom, and Canadian magnetic resonance imaging screening trials.
        Clin Cancer Res. 2007; 13: 7357-7362
        • Barrowdale D.
        • Pylkäs K.
        • Roberts J.
        • et al.
        Breast-cancer risk in families with mutations in PALB2.
        N Engl J Med. 2014; 371: 497-506
        • Haanpää M.
        • Pylkäs K.
        • Jukka S.
        • Moilanen J.S.
        • Winqvist R.
        Evaluation of the need for routine clinical testing of PALB2 c.1592delT mutation in BRCA negative Northern Finnish breast cancer families.
        Med Genet. 2013; 14: 1-6
        • Wesoła M.
        • Jeleń M.
        The risk of breast cancer due to PALB2 gene mutations.
        Adv Clin Exp Med. 2017; 26: 339-342
        • Jakubowska A.
        • Byrski T.
        • Gronwald J.
        • et al.
        Survival from breast cancer in patients with CHEK2 mutations.
        Breast Cancer Res Treat. 2014; 144: 397-403
        • Intra M.
        • Trentin C.
        • Corso G.
        • Veronesi P.
        CDH1 germline mutations and hereditary lobular breast cancer.
        Fam Cancer. 2016; 15: 215-219
        • Gibson G.
        Rare and common variants: twenty arguments.
        Nat Rev Genet. 2012; 13: 135-145
        • Koh G.L.
        • Wong E.S.Y.
        • Law H.Y.
        • et al.
        Identification of novel breast cancer risk loci.
        Cancer Res. 2017; 77: 5428-5437
        • Colditz G.A.
        • Bohlke K.
        • Berkey C.S.
        Breast cancer risk accumulation starts early – prevention must also.
        Breast Cancer Res Treat. 2014; 145: 567-579
        • Pankratz V.S.
        • Dupont W.D.
        • Vierkant R.A.
        • et al.
        Stratification of breast cancer risk in women with atypia: a Mayo cohort study.
        J Clin Oncol. 2007; 25: 2671-2677
        • van Leeuwen F.E.
        • Holowaty E.
        • Glimelius B.
        • et al.
        Cumulative absolute breast cancer risk for young women treated for Hodgkin lymphoma.
        J Natl Cancer Inst. 2005; 97: 1428-1437
        • Birdwell R.L.
        • Feng Y.
        • Neuberg D.S.
        • et al.
        Prospective study of the efficacy of breast magnetic resonance imaging and mammographic screening in survivors of Hodgkin lymphoma.
        J Clin Oncol. 2013; 31: 2282-2288
        • Harms S.
        • Leach M.O.
        • Lehman C.D.
        • et al.
        American cancer society guidelines for breast cancer screening with MRI as an adjunct to mammography.
        CA Cancer J Clin. 2007; 57: 75-89
        • Heydarian M.
        • Tsang R.
        • Pintilie M.
        • et al.
        Individualized estimates of second cancer risks after contemporary radiation therapy for Hodgkin lymphoma.
        Cancer. 2007; 110: 2576-2586
        • Amirikia K.C.
        • Bush P.M.
        Higher population-based incidence rates of triple-negative breast cancer among Young African American women: implications for breast cancer screening recommendations.
        Cancer. 2011; 117: 2747-2753
        • Yaffe M.J.
        • Mainprize J.G.
        Risk of radiation-induced breast cancer by mammographic screening.
        Radiology. 2011; 258: 98-105
        • McGeechan K.
        • Howard K.
        • Houssami N.
        Informed choice in mammography screening.
        Arch Intern Med. 2007; 167: 2039-2046